Palliative Low-Dose Radiotherapy Improves Pain in Hepatic Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 10, 2024 -- For adults with hepatocellular carcinoma or liver metastases, low-dose liver radiotherapy plus best supportive care improve pain compared with best supportive care alone, according to a study published online Sept. 5 in The Lancet Oncology.
Laura A. Dawson, M.D., from the Princess Margaret Cancer Centre at the University of Toronto, and colleagues conducted a randomized controlled phase 3 trial in nine cancer centers in Canada involving adults with hepatocellular carcinoma or liver metastases, who were refractory to standard treatment. After stratification by center and type of cancer, patients were randomly assigned to single-fraction radiotherapy (8 Gy) to the liver with 8 mg ondansetron (or equivalent) orally and 4 mg dexamethasone orally given before radiotherapy plus best supportive care or to best supportive care alone (33 patients were assigned to each group).
The researchers observed an improvement in hepatic pain of at least 2 points in worst pain intensity on the Brief Pain Inventory at one month in 67 percent of 24 patients and 22 percent of 18 patients in the group receiving radiotherapy plus best supportive care and the group receiving best supportive care only, respectively. Within one month after randomization, the most common grade 3 to 4 adverse events were abdominal pain and ascites. There were no serious adverse events or treatment-related deaths reported.
"Given the statistically and clinically significant reduction in pain compared with best supportive care alone at one month, this intervention could become a standard of care treatment for patients with hepatic cancer pain," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Moderate Hypofractionation Shows Good Safety Outcomes in Breast Cancer
MONDAY, Sept. 16, 2024 -- For patients with breast cancer, moderate hypofractionation (MHF) shows an improved safety profile, cosmesis, and quality of life compared with...
Long-Course Chemoradiotherapy Preferred TNT Regimen for Rectal Cancer
THURSDAY, Sept. 12, 2024 -- For patients with locally advanced rectal cancer pursuing organ preservation, long-course chemoradiotherapy (LCCRT) is the preferred total neoadjuvant...
Women With Liver Cancer Less Likely Than Men to Receive Liver Transplant
MONDAY, Sept. 9, 2024 -- Women with hepatocellular carcinoma (HCC) are less likely to receive a deceased-donor liver transplant (DDLT) and more likely to die while...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.